TACSTD2 and neoplasm: Besides, overexpression of TROP2 decreases the expression level of desmoglein 2 (DSG2), activates EGFR-AKT and DSG2-plakoglobin(PG)-β-catenin pathways to promote tumor cell invasion and migration (22).